Dr. Lal Path Labs Ltd.

rs 30

pany 70+ years of experience in the field of diagnostics 85.7 Mn patients serviced in last 5 years 30 NABL accredited Labs; National Reference Lab accredited by CAP As on March 31, 2021 Classificati

15%

in in the country with PAN India presence and consistent track record of quality and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. C

22%

N India presence and consistent track record of quality and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 La

200%

consistent track record of quality and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 Labs; Geographically spr

86%

and growth 15% 3 Year Revenue CAGR 22% 3-Year PAT CAGR 200% Equity Dividend for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 Labs; Geographically spread out network Rs. 1,137 crore Ca

Rs. 1,137 crore

for FY 20-21 ~86% ROCE Excl. Cash & Investments 231 Labs; Geographically spread out network Rs. 1,137 crore Cash & Investments as on 30th Sept, 21 5,008 Pathology & Radiology tests; Comprehensive Test

15.4%

Indian healthcare industry As on March 31, 2021 Classification: Restricted 5 Q2 FY22 Snapshot 15.4% INR 498.4 Cr Revenues 13.1% INR 152.2 Cr Normalised EBITDA 10.6% INR 96.3 Cr PAT 28.5% 6.

INR 498.4

healthcare industry As on March 31, 2021 Classification: Restricted 5 Q2 FY22 Snapshot 15.4% INR 498.4 Cr Revenues 13.1% INR 152.2 Cr Normalised EBITDA 10.6% INR 96.3 Cr PAT 28.5% 6.9 Mn Patien

13.1%

on March 31, 2021 Classification: Restricted 5 Q2 FY22 Snapshot 15.4% INR 498.4 Cr Revenues 13.1% INR 152.2 Cr Normalised EBITDA 10.6% INR 96.3 Cr PAT 28.5% 6.9 Mn Patients 33.4% 17.6 Mn

INR 152.2

ch 31, 2021 Classification: Restricted 5 Q2 FY22 Snapshot 15.4% INR 498.4 Cr Revenues 13.1% INR 152.2 Cr Normalised EBITDA 10.6% INR 96.3 Cr PAT 28.5% 6.9 Mn Patients 33.4% 17.6 Mn Samples Cl

10.6%

ricted 5 Q2 FY22 Snapshot 15.4% INR 498.4 Cr Revenues 13.1% INR 152.2 Cr Normalised EBITDA 10.6% INR 96.3 Cr PAT 28.5% 6.9 Mn Patients 33.4% 17.6 Mn Samples Classification: Restricted 6

INR 96.3

5 Q2 FY22 Snapshot 15.4% INR 498.4 Cr Revenues 13.1% INR 152.2 Cr Normalised EBITDA 10.6% INR 96.3 Cr PAT 28.5% 6.9 Mn Patients 33.4% 17.6 Mn Samples Classification: Restricted 6 Key Perfor